Emergent Biosolutions Inc. $EBS Shares Purchased by American Century Companies Inc.

American Century Companies Inc. raised its position in shares of Emergent Biosolutions Inc. (NYSE:EBS) by 3.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 2,382,378 shares of the biopharmaceutical company’s stock after acquiring an additional 90,216 shares during the period. American Century Companies Inc. owned approximately 4.54% of Emergent Biosolutions worth $21,013,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Millennium Management LLC lifted its stake in shares of Emergent Biosolutions by 68.9% in the 1st quarter. Millennium Management LLC now owns 2,502,488 shares of the biopharmaceutical company’s stock valued at $12,162,000 after purchasing an additional 1,020,582 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Emergent Biosolutions by 12.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,090,655 shares of the biopharmaceutical company’s stock valued at $5,301,000 after purchasing an additional 121,583 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in Emergent Biosolutions by 5.9% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 986,673 shares of the biopharmaceutical company’s stock valued at $6,295,000 after purchasing an additional 55,046 shares during the period. Acadian Asset Management LLC raised its position in Emergent Biosolutions by 17.0% in the second quarter. Acadian Asset Management LLC now owns 974,590 shares of the biopharmaceutical company’s stock valued at $6,216,000 after purchasing an additional 141,274 shares during the period. Finally, ProShare Advisors LLC acquired a new position in shares of Emergent Biosolutions during the second quarter worth about $71,000. 78.40% of the stock is currently owned by institutional investors and hedge funds.

Emergent Biosolutions Stock Performance

Emergent Biosolutions stock opened at $8.37 on Tuesday. Emergent Biosolutions Inc. has a 52 week low of $4.02 and a 52 week high of $14.06. The company has a current ratio of 5.01, a quick ratio of 2.41 and a debt-to-equity ratio of 1.09. The stock has a market cap of $439.59 million, a P/E ratio of 9.96 and a beta of 2.41. The stock has a 50 day moving average of $11.21 and a 200-day moving average of $10.40.

Emergent Biosolutions (NYSE:EBS) last issued its quarterly earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.54). Emergent Biosolutions had a return on equity of 15.86% and a net margin of 7.08%.The company had revenue of $148.70 million during the quarter, compared to the consensus estimate of $217.50 million. On average, analysts expect that Emergent Biosolutions Inc. will post -0.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the company. Weiss Ratings lowered Emergent Biosolutions from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, March 2nd. HC Wainwright dropped their price objective on shares of Emergent Biosolutions from $15.00 to $12.00 and set a “buy” rating on the stock in a research note on Monday. Finally, Wall Street Zen cut shares of Emergent Biosolutions from a “buy” rating to a “hold” rating in a research report on Sunday. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Emergent Biosolutions has a consensus rating of “Hold” and an average target price of $12.00.

Emergent Biosolutions Profile

Emergent BioSolutions is a global specialty biopharmaceutical company focused on developing, manufacturing and commercializing medical countermeasures and specialty products that address public health threats. The company’s portfolio includes vaccines, antibody therapies and critical care products designed to protect against biological, chemical and emerging infectious disease threats. Emergent has longstanding partnerships with government agencies, including the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), to support national preparedness programs.

Key commercial products in Emergent’s lineup include BioThrax (anthrax vaccine adsorbed), ACAM2000 (smallpox vaccine) and Vaxchora (cholera vaccine), alongside therapeutic treatments such as Anthrasil (anthrax immune globulin) and the naloxone-based nasal spray Narcan for opioid overdose reversal.